BRAF and non-small cell lung carcinoma: In cohort B of the above-mentioned BRF113928 trial, the clinical activity and safety of dabrafenib (150 mg twice daily) plus oral trametinib (2 mg once daily) were investigated in 57 pretreated BRAF V600E-mutant metastatic NSCLC patients.